| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Zandatrigine targets the voltage-gated sodium channel NaV1.6, which is encoded by the SCN8A gene. NaV1.6 is a subtype of sodium channel that is highly expressed in the central nervous system and plays a critical role in the generation and propagation of action potentials. By blocking this channel, Zandatrigine reduces neuronal excitability, which is beneficial in conditions like epilepsy where hyperexcitability is a hallmark.
|
|---|---|
| ln Vitro |
In vitro, Zandatrigine is characterized as a selective blocker of the NaV1.6 sodium channel. Specific IC50 values for channel inhibition are not provided in the available sources. Its activity is typically assessed in electrophysiological assays measuring sodium currents in cells expressing the NaV1.6 channel.
|
| ln Vivo |
In vivo, Zandatrigine is being studied for the treatment of epilepsy and other nervous system pathologies. Its ability to penetrate the blood-brain barrier is crucial for its central effects. Specific in vivo efficacy data, such as effects in animal models of epilepsy, are not detailed in the available sources.
|
| Enzyme Assay |
A cell-free assay for Zandatrigine is not applicable as it targets a voltage-gated ion channel. Its activity is assessed in cell-based electrophysiological assays. The compound's binding affinity to the NaV1.6 channel can be studied using radioligand binding assays with membrane preparations expressing the channel.
|
| Cell Assay |
Cellular assays for Zandatrigine typically involve electrophysiological recordings of sodium currents in cells expressing the NaV1.6 channel. Cells are treated with the compound, and the inhibition of sodium currents is measured. This allows for the determination of the compound's potency and state-dependence of block.
|
| Animal Protocol |
In vivo animal experiments for Zandatrigine are not described in the available sources. As a compound being developed for epilepsy, it would be evaluated in animal models of seizures. However, no specific protocols or data are provided.
|
| ADME/Pharmacokinetics |
Zandatrigine has a molecular formula of C22H25FN4O2S2 and a molecular weight of 460.59 g/mol. It is a solid. It is orally active and can cross the blood-brain barrier. Specific pharmacokinetic parameters, such as half-life and bioavailability, are not provided in the available sources. For storage, the powder should be kept at -20°C for up to 3 years.
|
| Toxicity/Toxicokinetics |
Toxicity data for Zandatrigine are not provided in the available sources. As a research compound, it is intended for research use only and is not for human consumption. Standard laboratory safety precautions should be observed.
|
| References | |
| Additional Infomation |
Zandatrigine (CAS: 2154406-04-7) is a selective, orally active inhibitor of the voltage-gated sodium channel NaV1.6 (SCN8A). It is also known as NBI-921352 and XEN901. The compound is being studied for the treatment of epilepsy and other nervous system pathologies. It is not an approved drug and is strictly for research purposes.
|
| Molecular Formula |
C22H25FN4O2S2
|
|---|---|
| Molecular Weight |
460.58790564537
|
| Exact Mass |
460.14
|
| CAS # |
2154406-04-7
|
| Related CAS # |
2154406-05-8 (formate);2154406-04-7;
|
| PubChem CID |
132141687
|
| Appearance |
White to light yellow solid powder
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
686
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
S(C1C(=CC(=C(C)C=1)N(C)[C@@H]1CN(CC2C=CC=CC=2)CC1)F)(NC1=CSC=N1)(=O)=O
|
| InChi Key |
UCSHINHOAVARGQ-SFHVURJKSA-N
|
| InChi Code |
InChI=1S/C22H25FN4O2S2/c1-16-10-21(31(28,29)25-22-14-30-15-24-22)19(23)11-20(16)26(2)18-8-9-27(13-18)12-17-6-4-3-5-7-17/h3-7,10-11,14-15,18,25H,8-9,12-13H2,1-2H3/t18-/m0/s1
|
| Chemical Name |
4-[[(3S)-1-benzylpyrrolidin-3-yl]-methylamino]-2-fluoro-5-methyl-N-(1,3-thiazol-4-yl)benzenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~271.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1711 mL | 10.8556 mL | 21.7113 mL | |
| 5 mM | 0.4342 mL | 2.1711 mL | 4.3423 mL | |
| 10 mM | 0.2171 mL | 1.0856 mL | 2.1711 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
